Pfizer Inc. (PFE)

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421). BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted.

Pfizer is dealing with headwinds right now, but they aren't unusual headwinds in the pharmaceutical sector. The company is taking aggressive actions to get back on track and recently stated it plans to support its dividend.

In the latest China pharmaceutical industry collaboration pact with a global drug leader, Hangzhou Sciwind Biosciences said today it had reached an agreement with Pfizer China to team up on the commercialization of a new-generation weight management and diabetes treatment, in a deal worth up to $495 million for the Chinese company.

This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

Dakota Wealth Management grew its stake in shares of Pfizer Inc. (NYSE: PFE) by 33.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 348,386 shares of the biopharmaceutical company's stock after acquiring an additional 87,308 shares during the period. Dakota Wealth Management's holdings in Pfizer

Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments of up to $495 million if milestones are met, the Chinese drugmaker said on Tuesday.

Novo Nordisk (NVO) is experiencing a significant drop in stock value after its obesity drug candidate, CagriSema, failed to meet the primary endpoint in the RED

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and we.

Installation of second Physical AI platform positions Telescope Innovations to successfully address the rapidly expanding SDL market Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 2026.

It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.

Pfizer (PFE 0.73%) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and analyst upside, this defensive giant may be quietly positioning for a rebound.

Pfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs. PFE's dividend is currently covered by cash flow, but payout ratios are stretched, and sustainability is questionable beyond 2027 without new revenue streams. Recent acquisitions, notably Metsera, increase leverage and are dilutive near-term but aim to offset $17–18B annual patent expirations by 2028.

The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind competitors, but is making aggressive moves to catch up.

AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions.